John Lee
2020 - PhaseBio Pharmaceuticals
In 2020, John Lee earned a total compensation of $910.2K as Chief Medical Officer at PhaseBio Pharmaceuticals, a 17% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $150,000 |
|---|---|
| Option Awards | $328,000 |
| Salary | $423,067 |
| Other | $9,159 |
| Total | $910,226 |
Lee received $423.1K in salary, accounting for 46% of the total pay in 2020.
Lee also received $150K in non-equity incentive plan, $328K in option awards and $9.2K in other compensation.
Rankings
In 2020, John Lee's compensation ranked 9,009th out of 13,090 executives tracked by ExecPay. In other words, Lee earned more than 31.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,009 out of 13,090 | 31st |
Division Manufacturing | 3,850 out of 5,621 | 32nd |
Major group Chemicals And Allied Products | 1,555 out of 2,254 | 31st |
Industry group Drugs | 1,358 out of 1,954 | 31st |
Industry Pharmaceutical Preparations | 1,005 out of 1,459 | 31st |
Source: SEC filing on April 22, 2022.
Lee's colleagues
We found two more compensation records of executives who worked with John Lee at PhaseBio Pharmaceuticals in 2020.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019